Former chef now hematologist/oncologist Views and opinions are my own.
- Tweets 2,121
- Following 1,911
- Followers 3,371
- Likes 11,264
Gabriel Aleixo retweeted
Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Nominating Committee. Visit asco.org/election to learn more about the candidates and place your vote!
24
48
5,079
Gabriel Aleixo retweeted
#Voting for @ASCO Election is now open.
I am #honored & #humbled to be running as one of the candidates, for the #ASCO #NominatingCommittee, alongside many remarkable talented candidates & GREAT colleagues.
Visit asco.org/election to learn more about the candidates & place your vote!
3
47
160
15,280
Gabriel Aleixo retweeted
Reproducibility Status of Economic Evaluations of Cancer Drugs: An Assessment of 150 Cost-Effectiveness Models.
Read the full article. bit.ly/4eERkLu
1
2
318
Gabriel Aleixo retweeted
Enjoyed the opportunity to present our work developing an AI-powered novel histopathologic biomarker in early-stage NSCLC at the @eaonc Data Science Committee meeting.
Thank you for the invitation @ValsamoA!
#LCSM #DigitalPathology #LungCancer
@CharuAggarwalMD @valarlabs
1
5
11
462
Gabriel Aleixo retweeted
Should be required reading for all oncology trainees, by one of the oncology and @ASCO giants Dr. Joseph Jacobson
cc: @guptaarjun90 @fischmd
healthaffairs.org/doi/10.137…
4
12
28
Gabriel Aleixo retweeted
Tafasitamab + Revlimid + RCHOP will never have a place in frontline DLBCL treatment. Way too toxic and huge pain in ass to give for docs and patients. Not worth very modest PFS benefit.
10
3
68
8,560
Gabriel Aleixo retweeted
Unfortunately, we are seeing more of this everyday. I do wish health systems did more to address the existential distress of dying patients nytimes.com/2026/10/04/magaz…
3
3
381
Gabriel Aleixo retweeted
Sharing our work evaluating the prognostic potential of a novel AI-powered histopathological biomarker in patients with resected stage I-III NSCLC
mdpi.com/4073794
#LCSM #DigitalPathology #LungCancer
@CharuAggarwalMD @MMarmarelis @NimgaonkarVivek @tjroycemd @Cancers_MDPI
2
2
12
436
Gabriel Aleixo retweeted
How do we identify which cancer patients will benefit most from cardioprotection?
In this review, our team discusses a risk-guided approach that combines baseline and ongoing risk assessment to support more personalized #CardioOnc care.
📰tinyurl.com/tn7wr3ue
1
13
31
1,164
Gabriel Aleixo retweeted
BIG TARLATAMAB MONITORING UPDATE @drshieldsmd
For C1D1 + C1D8:
⏱️ 22-24 hr observation ➡️ 6-8 hrs
📍 Stay within 1 hr of appropriate healthcare for 48 hrs
🩺 Follow-up assessment on Days 2 + 9
Much more practical for patients. #WCLC26
@AmgenOncology received approval on September 14, 2026 to REDUCE the recommended monitoring period for tarlatamab, which is currently FDA approved for the 2L setting for ES-SCLC.
Specifically, this approved label update reduces the recommended monitoring for cycle 1 day 1 and day 8 of tarlatamab:
⭐️ observation 22-24 hrs ➡️ 6-8 hrs
⭐️ vital signs & assessment follow up on the subsequent day (days 2 & 9)
Note: Patients should remain within 1 hr of the appropriate healthcare setting for 48 hrs, following cycle 1 day 1 and day 8, and care partner support is encouraged.
🔑 These vital updates help our SMASHERS gain improved access to life-changing therapeutics by reducing barriers, such as need for hospitalization for administration and monitoring.
‼️Unmet need: Validated risk assessment tools will be helpful to identify those who may be at risk for high grade CRS and early interventions.
@SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO
1
11
38
6,340
Gabriel Aleixo retweeted
🏥 #ASCOAI: As #AI reshapes #cancercare, patients must remain at the center.
@jamecancerdoc of @ClevelandClinic discusses why AI’s potential should be measured by whether it can expand access to affordable, high-quality care.
Watch the video ➡️ ascoai.org/videos/newsreels/…
2
11
911
Gabriel Aleixo retweeted
@StephenVLiu @LeXiuning @OncBrothers @HemOncFellows @GlopesMd @APassaroMD @lungoncdoc @NarjustFlorezMD @DevikaDasMD @DrJNaidoo @Lung_Cancers @DrSanjayPopat @tnewsomdavis @Tony_Calles @dmavicente @FordePatrick @LuisRaezMD @imedverse @Latinamd @ilyassahinMD @acmoorephd @DipeshUpretyMD @g_mountzios @dmavicente @drshieldsmd @DrRiyazShah @Innov_Medicine @guicorreiamd @drgandara @dplanchard @ozdogan_md @PatrickCMa1 @LungSummit @BRicciutiMD @BrunaPellini @chulkimMD @MARIANOPROVENCI @peters_solange @NReguart @FawziAbuRous @AlexSpiraMDPhD @dr_yakupergun @ipreeshagul @TomVargheseJr @SclcSMASHERS @BalazsHalmosMD
3
10
888
Gabriel Aleixo retweeted
Check out Dr. Rozenbaum's free comprehensive mechanical ventilation course: themvedproject.com/comprehen…. The videos cover foundations to advanced concepts, such as advanced mechanics, esophageal pressure monitors, & dyssynchronies. Claim free CME credits as you complete each module!
2
6
20
3,336
Gabriel Aleixo retweeted
🚨🔥@OncoAlert Hot off the press.
#BigNews #PressRelease by @SMMT_TX
⭐️ #HARMONi2 phase 3 trial of 1st line #Ivonescimab vs #Pembrolizumab in pts with #PDL1+ advanced non-small-cell #LungCancer (which previously showed #PFS benefit) now showing:
✅Statistically Significant ⬆️
#OverallSurvival (#OS) Benefit
👇🏻
tinyurl.com/57ceprfx
🚨🔥@OncoAlert Hot off the press
Just published @TheLancet
Results of #HARMONi2 phase 3 trial of #Ivonescimab (#PD1 & #VEGF Ab) vs #Pembrolizumab in pts with #PDL1+ advanced non-small cell #LungCancer in China.
⬆️#mPFS: 11.1 vs 5.8 months #HR: 0.51
👇🏻
thelancet.com/journals/lance…
1
9
40
3,026
Gabriel Aleixo retweeted
Hear the story of how, over a century a work, scientists linked high cholesterol with heart disease.
#meded #health #lipids
open.spotify.com/episode/5Gp…
1
2
2
276
Gabriel Aleixo retweeted
We are excited to welcome Dr. Anirudh Yalamanchali to the Department of Hematology and Medical Oncology at the @ClevelandClinic Cancer Institute.
Dr. Yalamanchali earned his Doctor of Medicine degree from Indiana University School of Medicine, completed his Internal Medicine Residency at @CCF_IMCHIEFS and completed his @ccfhemonc .
His clinical and research interests include head and neck cancer, melanoma, novel therapeutics, and theranostics.
Please join us in warmly welcoming Dr. Yalamanchali @CleClinicMD
3
29
1,898
Gabriel Aleixo retweeted
Have you checked out #HemeTalks yet?
In the new HemeTalks, Dr. Adam DuVall @AyaOncologist shares practical, current guidance on B-ALL. Explore treatment approaches for newly diagnosed and relapsed/refractory disease and compare approved CAR-T therapies.
🎧Listen ow.ly/eq7150ZIh05
#Hematology
1
3
613
Gabriel Aleixo retweeted
We are entering a new frontier in AML ➡️The Paradigm study now out in @NEJM showing improved EFS in younger non-fav. risk AML Tx with Aza/Ven vs. Intensive chemo. Huge congrats to Amir Fathi & all authors for this incredibly important study & milestone. nejm.org/doi/full/10.1056/NE…
6
36
109
17,385
Gabriel Aleixo retweeted
and some thoughts on how this is a missing part of our education - ascopubs.org/doi/10.1200/JCO…
1
7
247